Form 4: Revolution Medicines' Chief Operating Officer Sells Shares to Cover Tax Obligations

Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 4,415 shares of common stock on June 17, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Summary

• Margaret Horn, the Chief Operating Officer of Revolution Medicines, sold 4,415 shares of the company's common stock on June 17, 2024.
• The sale was executed at a weighted average price of $37.387 per share, with individual trades ranging from $37.3868 to $37.3875.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax obligations arising from the vesting of restricted stock units (RSUs).
• Following the transaction, Horn still beneficially owns 136,651 shares, which includes 85,726 RSUs and 1,513 shares acquired through the Employee Stock Purchase Plan on May 31, 2024.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax obligations) by an insider, which is neither particularly positive nor negative. The use of a 10b5-1 plan suggests transparency and pre-planning.

Industry Context

Insider sales are a common occurrence, especially when tied to pre-arranged trading plans like Rule 10b5-1, which allows insiders to sell shares without being accused of trading on non-public information. These sales are often related to tax obligations or diversification strategies.

Stakeholder Impact

• The sale of shares by an insider could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.

Key Dates